OvaScience Inc. (OVAS)
(Delayed Data from NSDQ)
$0.69 USD
0.00 (0.00%)
Updated Dec 7, 2018 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Tempest Therapeutics, Inc. [OVAS]
Reports for Purchase
Showing records 1 - 20 ( 92 total )
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ValuEngine Detailed Valuation Report for OVAS
Provider: ValuEngine, Inc
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Dropping Coverage
Provider: H.C. Wainwright & Co., Inc.
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Refocus on Science Should Aid in the Long Term; Reit Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q17 Update: Continued Focus on OvaPrime and OvaTure Lays Groundwork for Catalysts Ahead
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Corrected - Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are dropping coverage of OVAS shares to reallocate our research resources.
Provider: Roth Capital Partners, Inc.
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Coverage Update - Healthcare
Provider: Roth Capital Partners, Inc.
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Initial Clinical Readout From OvaPrime by Year-End Is Next Catalyst
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We are transferring coverage of OVAS to Sa''ar Yaniv from Scott Henry as part of a realignment process for our Healthcare coverage universe. Shares of OVAS were previously Under Review, with no estimates or price target
Provider: Roth Capital Partners, Inc.
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Our Thoughts on the Next Augment Study and 3Q Update
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Dropping Coverage Due to Analyst Departure
Provider: WEDBUSH SECURITIES INC.
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
You Only Launch Twice; We Maintain Our Buy Rating and Lower PT to $15
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Ideas List -- September 2015 Performance
Provider: WEDBUSH SECURITIES INC.
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Procedure Update Questions the "When" - "If" Story Seems Intact - IVF Clinic Consolidation Delays UAE Ramp - Lowering PT from $46 to $15 - Maintain OP
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Sliding OVAS Off the Wedbush Best Ideas List - Less Optimism for Near Term Positive Catalysts - 2016 Consensus Not Helping Matters - Maintain OP
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Egg splitting Publication Slightly Better than Our Thinking - No New Volume or Sales Visibility - Maintain OP
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z
Company: Tempest Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Egg splitting Publication Slightly Better than Our Thinking - No New Volume or Sales Visibility - Maintain OP
Provider: WEDBUSH SECURITIES INC.
Analyst: KHURSHID Z